These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30741685)

  • 1. One Step Into the Future: New iPSC Tools to Advance Research in Parkinson's Disease and Neurological Disorders.
    Mohamed NV; Larroquette F; Beitel LK; Fon EA; Durcan TM
    J Parkinsons Dis; 2019; 9(2):265-281. PubMed ID: 30741685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From 2D to 3D: Development of Monolayer Dopaminergic Neuronal and Midbrain Organoid Cultures for Parkinson's Disease Modeling and Regenerative Therapy.
    Yeap YJ; Teddy TJW; Lee MJ; Goh M; Lim KL
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live imaging and isolation of dopaminergic neurons.
    Calatayud C; Carola G; Fernández-Carasa I; Valtorta M; Jiménez-Delgado S; Díaz M; Soriano-Fradera J; Cappelletti G; García-Sancho J; Raya Á; Consiglio A
    Sci Rep; 2019 May; 9(1):6811. PubMed ID: 31048719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery.
    Marotta N; Kim S; Krainc D
    Expert Opin Drug Discov; 2020 Apr; 15(4):427-441. PubMed ID: 31899983
    [No Abstract]   [Full Text] [Related]  

  • 5. Induced pluripotent stem cell-based studies of Parkinson's disease: challenges and promises.
    Sanchez-Danes A; Benzoni P; Memo M; Dell'Era P; Raya A; Consiglio A
    CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1114-27. PubMed ID: 24040813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stemming the hype: what can we learn from iPSC models of Parkinson's disease and how can we learn it?
    Jacobs BM
    J Parkinsons Dis; 2014; 4(1):15-27. PubMed ID: 24398656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the genetic complexity of Parkinson's disease by targeted genome edition in iPS cells.
    Calatayud C; Carola G; Consiglio A; Raya A
    Curr Opin Genet Dev; 2017 Oct; 46():123-131. PubMed ID: 28759872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease.
    Wu YY; Chiu FL; Yeh CS; Kuo HC
    Open Biol; 2019 Jan; 9(1):180177. PubMed ID: 30958120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Derived Induced Pluripotent Stem Cell-Based Models in Parkinson's Disease for Drug Identification.
    Kouroupi G; Antoniou N; Prodromidou K; Taoufik E; Matsas R
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32993172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can cellular models revolutionize drug discovery in Parkinson's disease?
    Schüle B; Pera RA; Langston JW
    Biochim Biophys Acta; 2009 Nov; 1792(11):1043-51. PubMed ID: 19733239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancing Drug Discovery for Neurological Disorders Using iPSC-Derived Neural Organoids.
    Costamagna G; Comi GP; Corti S
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells.
    Li H; Jiang H; Zhang B; Feng J
    J Parkinsons Dis; 2018; 8(4):479-493. PubMed ID: 30149462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.
    Sison SL; Vermilyea SC; Emborg ME; Ebert AD
    Curr Neurol Neurosci Rep; 2018 Oct; 18(12):84. PubMed ID: 30284665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into GBA Parkinson's disease pathology and therapy with induced pluripotent stem cell model systems.
    Baden P; Yu C; Deleidi M
    Neurobiol Dis; 2019 Jul; 127():1-12. PubMed ID: 30711484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells.
    Son MY; Sim H; Son YS; Jung KB; Lee MO; Oh JH; Chung SK; Jung CR; Kim J
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):584-603. PubMed ID: 28235153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells.
    Stoddard-Bennett T; Reijo Pera R
    Cells; 2019 Jan; 8(1):. PubMed ID: 30621042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What we can learn from iPSC-derived cellular models of Parkinson's disease.
    Caiazza MC; Lang C; Wade-Martins R
    Prog Brain Res; 2020; 252():3-25. PubMed ID: 32247368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concise Review: Modeling Neurodegenerative Diseases with Human Pluripotent Stem Cell-Derived Microglia.
    Haenseler W; Rajendran L
    Stem Cells; 2019 Jun; 37(6):724-730. PubMed ID: 30801863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson's disease.
    Bose A; Beal MF
    Eur J Neurosci; 2019 Feb; 49(4):525-532. PubMed ID: 30408242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New transgenic models of Parkinson's disease using genome editing technology.
    Cota-Coronado JA; Sandoval-Ávila S; Gaytan-Dávila YP; Diaz NF; Vega-Ruiz B; Padilla-Camberos E; Díaz-Martínez NE
    Neurologia (Engl Ed); 2020 Sep; 35(7):486-499. PubMed ID: 29196142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.